Literature DB >> 10847627

Molecular regulation of the human inducible nitric oxide synthase (iNOS) gene.

B S Taylor1, D A Geller.   

Abstract

In critically ill patients, the human inducible nitric oxide synthase (iNOS) gene is expressed in nearly every organ and has been shown to be associated with the refractory hypotension of septic and hemorrhagic shock. The molecular regulation of iNOS expression is complex and occurs at multiple sites in the gene expression pathway. Work in our laboratory has demonstrated that a combination of cytokines synergistically activate iNOS expression, which has resulted in the cloning of the first human iNOS gene from cytokine-stimulated hepatocytes. In addition, we have demonstrated that iNOS expression is transcriptionally regulated and that the functional promoter elements are located upstream of -4.7 kilobases (kb) within a unique enhancer region containing four functional nuclear factor kappa B elements. These results contrast markedly with the murine iNOS promoter, where only 1.0 kb of 5'-flanking sequence is required for lipopolysaccharide and cytokine responsiveness. Furthermore, numerous mechanisms have evolved to down-regulate iNOS expression. By elucidating these mechanisms, therapeutic strategies to govern iNOS expression may be developed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10847627     DOI: 10.1097/00024382-200006000-00001

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  35 in total

Review 1.  Mechanisms of immune resolution.

Authors:  Alfred Ayala; Chun-Shiang Chung; Patricia S Grutkoski; Grace Y Song
Journal:  Crit Care Med       Date:  2003-08       Impact factor: 7.598

Review 2.  Nitric oxide and redox regulation in the liver: Part I. General considerations and redox biology in hepatitis.

Authors:  Diana L Diesen; Paul C Kuo
Journal:  J Surg Res       Date:  2009-10-09       Impact factor: 2.192

3.  PATHOLOGICAL ASPECTS OF THE ANTI-INFLAMMATORY/IMMUNE SUPPRESSIVE RESPONSE IN SEPSIS AND SHOCK.

Authors:  Alfred Ayala; Yanli Ding; Rebecca J Rhee; Lesley A Doughty; Patrician S Grutkoski; Chun-Shiang Chung
Journal:  Rec Res Dev Immunol       Date:  2003-01-12

4.  Dysbiosis-induced intestinal inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver disease in mice.

Authors:  Peng Chen; Peter Stärkel; Jerrold R Turner; Samuel B Ho; Bernd Schnabl
Journal:  Hepatology       Date:  2015-01-30       Impact factor: 17.425

5.  Gemfibrozil, a lipid-lowering drug, inhibits the induction of nitric-oxide synthase in human astrocytes.

Authors:  Kalipada Pahan; Malabendu Jana; Xiaojuan Liu; Bradley S Taylor; Charles Wood; Susan M Fischer
Journal:  J Biol Chem       Date:  2002-09-18       Impact factor: 5.157

Review 6.  Management of vasodilatory shock: defining the role of arginine vasopressin.

Authors:  Martin W Dunser; Volker Wenzel; Andreas J Mayr; Walter R Hasibeder
Journal:  Drugs       Date:  2003       Impact factor: 9.546

7.  Arginase blockade protects against hepatic damage in warm ischemia-reperfusion.

Authors:  Geetha Jeyabalan; John R Klune; Atsunori Nakao; Nicole Martik; Guoyao Wu; Allan Tsung; David A Geller
Journal:  Nitric Oxide       Date:  2008-04-14       Impact factor: 4.427

Review 8.  Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria.

Authors:  Guy C Brown; Anna Bal-Price
Journal:  Mol Neurobiol       Date:  2003-06       Impact factor: 5.590

9.  Bioluminescent detection of peroxynitrite with a boronic acid-caged luciferin.

Authors:  Nathan A Sieracki; Benjamin N Gantner; Mao Mao; John H Horner; Richard D Ye; Asrar B Malik; Martin E Newcomb; Marcelo G Bonini
Journal:  Free Radic Biol Med       Date:  2013-03-07       Impact factor: 7.376

10.  Elevated generation of reactive oxygen/nitrogen species in hantavirus cardiopulmonary syndrome.

Authors:  Ian C Davis; Allan J Zajac; Kurt B Nolte; Jason Botten; Brian Hjelle; Sadis Matalon
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.